Valeritas Appoints Chief Business Officer

Valeritas Holdings Inc., a medical technology company which offers patients with type 2 diabetes V-Go Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch and can eliminate the need for taking multiple daily shots, has appointed Joseph Saldanha as chief business officer, effective Jan. 29. In this newly created role, Saldanha will report to President and CEO John Timberlake.
 
“V-Go use is accelerating in the United States as our higher-service commercial model and patient education programs continue to demonstrate their effectiveness. Saldanha is the ideal addition to our management team and he shares our commitment to helping the millions of patients with type 2 diabetes reduce the need to take multiple daily injections,” said Timberlake. “His experience and knowledge of the U.S. and international diabetes market as well as his broad experience with diabetes drugs and devices, will be a great asset to Valeritas.”
 
Saldanha brings more than 25 years of medical technology and pharmaceutical experience to Valeritas, including extensive diabetes expertise. Most recently, Saldanha held the position of vice president, Marketing and Business Development at MannKind Corporation. Prior to that, he had domestic and international roles at Gulf Pharmaceuticals Industries – Julphar, Pfizer, Johnson & Johnson, Sanofi and Bristol-Myers Squibb in commercial, corporate and business development, alliance management, and manufacturing management.
 
Saldanha earned a bachelor of science degree in Commerce and Engineering Sciences from Drexel University and a master of science degree in Organizational Management from the University of Pennsylvania.
 
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with type 2 diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of patients with type 2 diabetes. Headquartered in Bridgewater, N.J., Valeritas operates its R&D functions in Marlborough, Mass.